NCT03428958 - A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

October 5, 2018

Primary Completion Date

March 19, 2024

Study Completion Date

March 21, 2024

Conditions

Colorectal CancerColorectal NeoplasmsColorectal CarcinomaColorectal TumorsNeoplasms, Colorectal

Interventions

DRUG

NUC-3373 + leucovorin

DRUG

NUC-3373

DRUG

NUFOX

NUC-3373 + oxaliplatin

DRUG

NUFOX + VEGF pathway inhibitor

NUC-3373 + oxaliplatin + bevacizumab

DRUG

NUFOX + EGFR inhibitor

NUC-3373 + oxaliplatin + cetuximab/panitumumab

DRUG

NUFIRI

NUC-3373 + irinotecan

DRUG

NUFIRI + VEGF pathway inhibitor

NUC-3373 + irinotecan + bevacizumab

DRUG

NUFIRI + EGFR inhibitor

NUC-3373 + irinotecan + cetuximab/panitumumab

DRUG

NUC-3373 + bevacizumab

Trial Locations (10)

27710

Duke University Medical Center, Durham

37232

Vanderbilt University, Nashville

92300

Hopital Franco-Britannique, Levallois-Perret

98684

Compass Oncology, Vancouver

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

98109-1023

Seattle Cancer Center, Seattle

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

W1T 7HA

University College London Hospitals NHS Foundation Trust, London

OX3 7LE

University of Oxford, Oxford